Ailment: Multiple Scleroris
U.S. Sales: $3.1 billion
Owner: Teva Pharmaceutical Industries.
Teva recently launched a new formulation of the drug that lasts longer than the standard version. Consumers have been quick to adopt the new version, which is good for the pharmaceutical manufacturer since a federal judge last month ruled that its patent is invalid.